-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WRR/1T/YBCM3mu/l9DLqM95io2skdpqnUM5bJhCstqExgG4ZaIvPv7uppL0wMsXQ V3dhr73ldylNBSgfFa5EPA== 0000950144-07-003524.txt : 20070418 0000950144-07-003524.hdr.sgml : 20070418 20070418151800 ACCESSION NUMBER: 0000950144-07-003524 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070413 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20070418 DATE AS OF CHANGE: 20070418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: eXegenics Inc CENTRAL INDEX KEY: 0000944809 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 752402409 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26648 FILM NUMBER: 07773324 BUSINESS ADDRESS: STREET 1: 1250 PITTSFORD-VICTOR ROAD STREET 2: BUILDING 200, SUITE 280 CITY: PITTSFORD STATE: NY ZIP: 14534 BUSINESS PHONE: 585-218-4368 MAIL ADDRESS: STREET 1: 1250 PITTSFORD-VICTOR ROAD STREET 2: BUILDING 200, SUITE 280 CITY: PITTSFORD STATE: NY ZIP: 14534 FORMER COMPANY: FORMER CONFORMED NAME: EXEGENICS INC DATE OF NAME CHANGE: 20011114 FORMER COMPANY: FORMER CONFORMED NAME: CYTOCLONAL PHARMACEUTICS INC /DE DATE OF NAME CHANGE: 19950503 8-K 1 g06767e8vk.htm EXEGENICS INC. eXegenics Inc.
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 13, 2007
eXegenics Inc.
(Exact Name of Registrant as Specified in Charter)
         
Delaware
(State or other
jurisdiction of
incorporation) 		  000-26648
(Commission
File Number) 		  75-2402409
(IRS Employer
Identification No.)
     
4400 Biscayne Blvd
Suite 900
Miami, Florida		   33137
(Address of Principal Executive Offices)   (Zip Code)
Registrant’s telephone number, including area code: (305) 575-6015
 
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 1.01. Entry into a Material Definitive Agreement
SIGNATURES

Table of Contents

Item 1.01. Entry into a Material Definitive Agreement
     On April 13, 2007, eXegenics Inc., a Delaware corporation (“eXegenics”), invested $5 million in Ophthalmic Technologies, Inc., an Ontario corporation (“OTI”) and entered into a definitive Share Purchase Agreement (the “Purchase Agreement”) with OTI and its shareholders. In exchange for the $5 million investment, OTI agreed to issue common shares of OTI to eXegenics to cause eXegenics to hold one-third of the equity in OTI on a fully diluted basis. The $5 million will be used by OTI for working capital.
     Under the Purchase Agreement, eXegenics received an exclusive option to purchase the remaining shares of OTI in exchange for the issuance of between 3.13 million and 2.82 million shares of common stock of eXegenics, depending upon the average per share closing price of eXegenics common stock for the ten (10) trading dates ended on the second business day prior to the exercise of the option. The aforesaid option shall extend for the greater of a period of (i) six (6) months from the date of the agreement and (ii) three (3) months from completion of OTI’s fiscal years ended April 30, 2006 and April 30, 2007 financial statement audits.

 

Table of Contents

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  eXegenics Inc.
 		  
Date April 18, 2007  By   /s/ Adam Logal   
    Name:   Adam Logal   
    Title:   Executive Director of Finance, Chief Accounting Officer, Treasurer and Secretary   
 
 

 

-----END PRIVACY-ENHANCED MESSAGE-----